Skip to main content
Top
Published in: Journal of Infection and Chemotherapy 6/2012

01-12-2012 | Original Article

Intrahost emergent dynamics of oseltamivir-resistant virus of pandemic influenza A (H1N1) 2009 in a fatally immunocompromised patient

Authors: Nobuyuki Hamada, Yutaka Imamura, Koyu Hara, Takahito Kashiwagi, Yoshihiro Imamura, Yoko Nakazono, Katsumi Chijiwa, Hiroshi Watanabe

Published in: Journal of Infection and Chemotherapy | Issue 6/2012

Login to get access

Abstract

The oseltamivir-resistant pandemic influenza virus A (2009 H1N1) with H275Y mutation in neuraminidase (NA) has been sporadically reported, and its wide spread remains a potential threat. Here we detected the uneven distribution of H275Y mutant virus in a patient who received a 21-day long-term administration of oseltamivir. Intrahost variation of the virus showed that the H275Y mutant virus was the predominant population in both nasopharynx and right lung, whereas the oseltamivir-sensitive virus comprised half the population in the left lung. By constructing minimum spanning trees, it is proposed that the H275Y mutant might be generated primarily in the nasopharynx, then spread to the right and left lungs.
Literature
1.
go back to reference Smith GJ, Vijaykrishna D, Bahl J, Lycett SJ, Worobey M, Pybuset OG, et al. Origins and evolutionary genomics of the 2009 swine-origin H1N1 influenza A epidemic. Nature (Lond). 2009;459:1122–5.CrossRef Smith GJ, Vijaykrishna D, Bahl J, Lycett SJ, Worobey M, Pybuset OG, et al. Origins and evolutionary genomics of the 2009 swine-origin H1N1 influenza A epidemic. Nature (Lond). 2009;459:1122–5.CrossRef
2.
go back to reference Baranovich T, Saito R, Suzuki Y, Zaraket H, Dapat C, Caperig-Dapat I, et al. Emergence of H274Y oseltamivir-resistant A (H1N1) influenza viruses in Japan during the 2008–2009 season. J Clin Virol. 2010;47:23–8.PubMedCrossRef Baranovich T, Saito R, Suzuki Y, Zaraket H, Dapat C, Caperig-Dapat I, et al. Emergence of H274Y oseltamivir-resistant A (H1N1) influenza viruses in Japan during the 2008–2009 season. J Clin Virol. 2010;47:23–8.PubMedCrossRef
3.
go back to reference Campanini G, Piralla A, Rovida F, Puzelli S, Facchini M, Locatelli F, et al. First case in Italy of acquired resistance to oseltamivir in an immunocompromised patient with influenza A/H1N1v infection. J Clin Virol. 2010;48:220–2.PubMedCrossRef Campanini G, Piralla A, Rovida F, Puzelli S, Facchini M, Locatelli F, et al. First case in Italy of acquired resistance to oseltamivir in an immunocompromised patient with influenza A/H1N1v infection. J Clin Virol. 2010;48:220–2.PubMedCrossRef
4.
go back to reference Hoelzer K, Murcia PR, Baillie GJ, Wood JL, Metzger SM, Osterrieder N, et al. Intrahost evolutionary dynamics of canine influenza virus in naive and partially immune dogs. J Virol. 2010;84:5329–35.PubMedCrossRef Hoelzer K, Murcia PR, Baillie GJ, Wood JL, Metzger SM, Osterrieder N, et al. Intrahost evolutionary dynamics of canine influenza virus in naive and partially immune dogs. J Virol. 2010;84:5329–35.PubMedCrossRef
5.
go back to reference Tamura K, Dudley J, Nei M, Kumar S. MEGA4: molecular evolutionary genetics analysis (MEGA) software version 4.0. Mol Biol Evol. 2007;24:1596–9.PubMedCrossRef Tamura K, Dudley J, Nei M, Kumar S. MEGA4: molecular evolutionary genetics analysis (MEGA) software version 4.0. Mol Biol Evol. 2007;24:1596–9.PubMedCrossRef
6.
go back to reference Ministry of Health: LaWoJ. Oseltamivir-resistant pandemic influenza virus in Kurume City. Press Release 26 February 2010. Ministry of Health: LaWoJ. Oseltamivir-resistant pandemic influenza virus in Kurume City. Press Release 26 February 2010.
7.
go back to reference Spada E, Sagliocca L, Sourdis J, Garbuglia AR, Poggi V, De Fusco C, et al. Use of the minimum spanning tree model for molecular epidemiological investigation of a nosocomial outbreak of hepatitis C virus infection. J Clin Microbiol. 2004;42:4230–6.PubMedCrossRef Spada E, Sagliocca L, Sourdis J, Garbuglia AR, Poggi V, De Fusco C, et al. Use of the minimum spanning tree model for molecular epidemiological investigation of a nosocomial outbreak of hepatitis C virus infection. J Clin Microbiol. 2004;42:4230–6.PubMedCrossRef
8.
go back to reference Furuse Y, Suzuki A, Kishi M, Nukiwa N, Shimizu M, Sawayama R, et al. Occurrence of mixed populations of influenza A viruses that can be maintained through transmission in a single host and potential for reassortment. J Clin Microbiol. 2010;48:369–74.PubMedCrossRef Furuse Y, Suzuki A, Kishi M, Nukiwa N, Shimizu M, Sawayama R, et al. Occurrence of mixed populations of influenza A viruses that can be maintained through transmission in a single host and potential for reassortment. J Clin Microbiol. 2010;48:369–74.PubMedCrossRef
9.
go back to reference Kryazhimskiy S, Plotkin JB. The population genetics of dN/dS. PLoS Genet. 2008;4:e1000304. Kryazhimskiy S, Plotkin JB. The population genetics of dN/dS. PLoS Genet. 2008;4:e1000304.
Metadata
Title
Intrahost emergent dynamics of oseltamivir-resistant virus of pandemic influenza A (H1N1) 2009 in a fatally immunocompromised patient
Authors
Nobuyuki Hamada
Yutaka Imamura
Koyu Hara
Takahito Kashiwagi
Yoshihiro Imamura
Yoko Nakazono
Katsumi Chijiwa
Hiroshi Watanabe
Publication date
01-12-2012
Publisher
Springer Japan
Published in
Journal of Infection and Chemotherapy / Issue 6/2012
Print ISSN: 1341-321X
Electronic ISSN: 1437-7780
DOI
https://doi.org/10.1007/s10156-012-0429-0

Other articles of this Issue 6/2012

Journal of Infection and Chemotherapy 6/2012 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine